Godrej Consumer Products Ltd (GCPL) on Monday announced that it expects to post high‑teens consolidated revenue growth in the September quarter, driven by healthy demand across markets. The company said that even as inflationary pressures intensified across several commodity‑linked inputs, its consolidated level would deliver another quarter of strong performance with high‑teens revenue growth, high‑single‑digit underlying volume growth and double‑digit EBITDA growth. At the standalone enterprise level, GCPL expects revenue growth in the teens and high‑single‑digit underlying volume growth despite an estimated impact of approximately 100‑150 basis points from trade inventory correction. The performance is supported by healthy growth across both its Personal Care and Home Care portfolios, reflecting broad‑based performance.

The domestic equity market is expected to open flat on Tuesday, October 6, with the GIFT NIFTY futures suggesting that the NIFTY50 index will open 8 points higher. In the same day, crude oil prices declined nearly 2%, with Brent settling at $100.32 a barrel and WTI at $89.43. The fall came as Middle East crude exports increased and G7 nations pledged to boost supplies, although ongoing geopolitical tensions and disruption risks in the region limited the decline. Lower crude prices could offer some relief to oil marketing companies, airlines, paints and other fuel‑intensive sectors, while upstream producers could see pressure on realisations.

Kotak Mahindra Bank shares will be in focus after the lender reported a 24.7% year‑on‑year increase in net advances to ₹5.77 lakh crore as of September 30, 2026. Total deposits rose 23.2% YoY to ₹6.51 lakh crore, while CASA deposits increased 11.3% to ₹2.49 lakh crore. The bank also reported $5.78 billion (around ₹55,344 crore) in FCNR(B) deposits under the RBI’s swap facility. Axis Bank shares will be in focus after the lender reported a 22.7% year‑on‑year increase in gross advances to ₹13.85 lakh crore as of September 30, 2026. Total deposits rose 20.7% YoY to ₹14.52 lakh crore, while CASA deposits grew 10.6% to ₹5.30 lakh crore. The bank also mobilised $10.62 billion (around ₹1.02 lakh crore) in FCNR(B) deposits under the RBI’s swap facility. Excluding loans linked to these FCNR(B) deposits, gross advances grew 18.8% YoY, while deposits rose 17% YoY.

Trent’s provisional business update shared on Monday showed its standalone revenue from operations, excluding GST, rose 23% year‑on‑year to ₹5,788 crore in Q2 FY27, compared with ₹4,724 crore a year ago. Revenue from merchandise sales, excluding other operating income, also grew 23% during the quarter. The company’s H1FY27 revenue rose 21% YoY to ₹11,454 crore. Vedanta is expected to be in focus after its board will meet this week to consider and approve its first interim dividend for FY27. In a regulatory filing, the company said it will meet on Thursday, October 8, 2026, for this purpose. The record date for determining the entitlement of equity shareholders for the said dividend, if declared, is being fixed as Wednesday, October 14, 2026.

Zydus Lifesciences Limited, in partnership with MSN Laboratories Private Limited, has launched the first generic version of Adempas (Riociguat tablets) in the US market, according to a regulatory filing. The launch covers Riociguat tablets in all five strengths: 0.5 mg, 1 mg, 1.5 mg, 2 mg and 2.5 mg. The product was developed and manufactured by MSN Laboratories and has received approval from the US Food and Drug Administration (USFDA) as a generic equivalent of Adempas tablets, according to the filing on Monday evening. Riociguat is a soluble guanylate cyclase (sGC) stimulator indicated for the treatment of adults with persistent or recurrent chronic thromboembolic pulmonary hypertension (CTEPH) after surgical treatment, or inoperable CTEPH. It is also indicated for adults with pulmonary arterial hypertension (PAH) to improve exercise capacity, functional class and delay clinical worsening.

Narayana Hrudayalaya Ltd on Monday said it has agreed to exclusively operate and manage Mission of Mercy Hospital and Research Centre on Park Street in Kolkata. The agreement with the hospital and the Assemblies of God of North India will enable Narayana Hrudayalaya to leverage its expertise in healthcare and hospital management to support the long‑term sustainability and service capacity. The existing hospital has a built‑up area of approximately 63,240.37 sq ft and a capacity of 100 beds. The agreement does not confer any ownership, lease rights or other interest in the underlying land to Narayana Hrudayalaya, according to the filing.